Polymorphic forms of 4-phenylamine quinazoline derivative, the preparation method and uses thereof
The present invention relates to polymorphic forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-toluenesulfonate with the characteristic X-ray powder diffraction data as stated in the description, preparation methods thereof, pharmaceutical compositions comprising the same and the use thereof.
1. Crystalline form C of the N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-Toluenesulfonate salt, characterized in that the X-ray powder diffraction pattern has peaks at the diffraction angle 2θ(°) of 3.40±0.10, 6.82±0.10, 7.58±0.10, 11.30±0.10, 14.84±0.10, 15.24±0.10, 17.28±0.10, 17.86±0.10, 18.34±0.10, 20.32±0.10, 22.96±0.10, 23.50±0.10, 24.12±0.10, 24.62±0.10, and 25.86±0.10.
2. Form C according to claim 1 , characterized in that the X-ray powder diffraction pattern also has peaks at the diffraction angle 2θ(°) of 9.04±0.10, 10.26±0.10, 22.44±0.10, 25.06±0.10, 26.98±0.10, 28.62±0.10, and 29.98±0.10.
3. Form C according to claim 1 , characterized in that the Form C has the X-ray powder diffraction pattern as substantially shown in FIG. 3 .
4. Form C according to claim 1 , characterized in that the Form C also has the IR spectrum as substantially shown in FIG. 7 .
5. A process for preparing a crystalline form C of the N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-Toluenesulfonate salt, comprising the steps of:
(a) dissolving the crystalline form A of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-Toluenesulfonate in the mixture of a protic solvent and an aprotic solvent;
(b) adding dropwise a solution formed from p-Toluenesulfonic acid in said mixture of a protic solvent and an aprotic solvent under stirring and controlling the molar ratio of Form A to p-Toluenesulfonic acid in the range of 1:1˜6;
(c) resulting in a crystalline precipitate, letting the resulting mixture stand, and filtering out and washing the crystal to obtain the target crystal.
6. A process according to claim 5 , wherein the protic solvent is water or the mixture of water and an alcohol.
7. A process according to claim 5 , wherein the aprotic solvent is selected from the group consisting of tetrahydrofuran, ether, dichloromethane, acetone, acetonitrile, DMF, and the mixtures thereof.
8. A process according to claim 5 , wherein the solution of the crystalline form A of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-Toluenesulfonate in the step (a) has a concentration of 3˜7 g/100 mL.
9. A process according to claim 5 , wherein the solution of p-Toluenesulfonic acid in the step (b) has a concentration of 10˜30 g/100 mL.
10. A process according to claim 5 , characterized in that the volume ratio of the protic solvent to the aprotic solvent in the mixture of a protic solvent and an aprotic solvent is 1:1˜5.
11. A process according to claim 5 , wherein the solution of the crystalline form A of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-Toluenesulfonate in the step (a) has a concentration of 3˜7 g/100 mL; the solution of p-Toluenesulfonic acid in the step (b) has a concentration of 10˜30 g/100 mL; the protic solvent is water; the aprotic solvent is tetrahydrofuran, and the volume ratio of tetrahydrofuran to water is 1˜5:1.
12. A pharmaceutical composition comprising the crystalline form C of the N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-Toluenesulfonate salt according to claim 1 and a pharmaceutically acceptable carrier.